![]() |
市場調查報告書
商品編碼
1433469
全球甲狀腺消融設備市場 2023-2030Global Thyroid Ablation Devices Market 2023-2030 |
預計全球甲狀腺消融設備市場在預測期(2023-2030年)將以9.8%的複合CAGR成長。該市場的成長歸因於甲狀腺癌盛行率的增加,這創造了對該設備的需求。美國癌症協會估計,2023 年美國甲狀腺癌新病例約為 43,720 例(男性 12,540 例,女性 31,180 例)。約 2,120 人死於甲狀腺癌(其中男性 970 人,女性 1,150 人)。一個人被診斷出患有甲狀腺癌的平均年齡是 51 歲。這種癌症在女性中的發生率約為男性的 3 倍,在白人中的發病率比在黑人中高出約 70%。此外,2022年11月,《老年人口統計:美國老化肖像》一文報道,有5,410萬成年人(占美國人口的16.3%)是老年人,其中包括65歲或以上的老年人。預計到2040年老年人口將增至22%,到2060年將增至25%。微創治療手術需求的不斷成長進一步創造了巨大的市場成長空間。
全球甲狀腺消融設備市場依類型、產品、應用和最終用途區隔。依類型,市場分為射頻消融、微波消融等。其中,其他包括影像導引消融。根據產品,市場分為熱敏設備和非熱敏設備。根據應用,市場分為甲狀腺癌和甲狀腺結節。此外,根據最終用途,市場區隔為醫院和診所、門診手術中心等。其中,其他包括癌症專科中心。在最終用途中,預計醫院和診所區隔市場將在預測期內佔據最大的市場佔有率。該區隔市場的大部分佔有率歸功於較低的成本、較高的效率和可用性。
其中,微波消融區隔市場預計將在預測期內成長,因為其治療時間較短、消融區域更寬且散熱效應較小。 MWA 系統由發電機、軟性電纜和天線組成。 《腺體外科》發表的一篇文章,題為“甲狀腺結節微波消融:經皮治療的新弓弦?”記錄了實驗研究和其他器官的研究,MWA可能是甲狀腺結節經皮技術的另一個進步,具有減少治療時間、減少散熱效應、創造最適合甲狀腺結節形狀的橢圓形消融區的優點。
全球甲狀腺消融設備市場根據地理位置進一步區隔,包括北美(美國和加拿大)、歐洲(英國、義大利、西班牙、德國、法國和歐洲其他地區)、亞太地區(印度、中國、日本、韓國和亞洲其他地區)以及世界其他地區(中東和非洲以及拉丁美洲。其中,亞太地區預計在預測期內將以相當大的CAGR成長。甲狀腺消融設備、老年人口的增加、醫療保健支出的增加以及甲狀腺癌症發生率的增加推動了亞太地區甲狀腺消融設備市場的發展。
預計在預測期內,北美將在甲狀腺消融設備市場中佔據顯著佔有率。推動北美市場的重要因素包括甲狀腺癌盛行率的增加、對微創手術的日益偏好以及技術上可靠的消融手術的可用性。此外,主要參與者正在擴大在該地區的業務,以滿足市場上對甲狀腺消融設備的需求。 2023年10月,韓國醫療器材公司STARmed Co., Ltd.成立了美國子公司STARmed America。這項策略性舉措凸顯了 STARmed 對改善北美患者照護的承諾,這是其更廣泛的全球擴張願景的一部分。 STARmed Co., Ltd. 一直處於熱消融創新的前沿,透過微創替代方案為患者提供舒適感。該公司專注於肝臟射頻消融 (RFA),並於 2009 年設計了第一個甲狀腺專用射頻電極。
服務甲狀腺消融設備市場的主要公司包括波士頓科學公司、Integra LifeSciences 公司、強生服務公司、美敦力公司等。市場參與者透過各種策略(包括併購、合作、合作、融資和新產品發布),為市場成長做出了巨大貢獻,以保持市場競爭力。例如,2023 年 11 月,美國食品藥物管理局 (FDA) 批准貝爾德醫療的微波消融 (MWA) 系統和一次性針頭在美國使用。這項許可證是透過 Baird Medical 子公司 Betters Medical 獲得的,這意味著美國的醫生現在可以使用該技術來消融甲狀腺結節、乳房腫瘤和其他需要切除軟組織的疾病。 2023年7月,中國國家藥品監督管理局(NMPA)批准該系統用於治療良性甲狀腺結節。
Global Thyroid Ablation Devices Market Size, Share & Trends Analysis Report by Type (Radiofrequency Ablation, Microwave Ablation, and Others), by Product (Thermal-based Devices and Non-thermal-based Devices), By Application, (Thyroid Cancer and Thyroid Nodules), by End-use (Hospitals and Clinics, Ambulatory Surgical Centers, and Others), Forecast Period (2023-2030)
The global thyroid ablation devices market is anticipated to grow at a considerable CAGR of 9.8% during the forecast period (2023-2030). The growth of this market is attributed to the increasing prevalence of thyroid cancer which has created demand for this device. In 2023, the American Cancer Society estimated thyroid cancer in the US, about 43,720 new cases of thyroid cancer (12,540 in men and 31,180 in women). About 2,120 deaths from thyroid cancer (970 in men and 1,150 in women). The average age when a person is diagnosed with thyroid cancer is 51. This cancer is about 3 times more common in women than in men, and it is about 70% more common in white people than in black people. In addition, in November 2022, the article "Senior Population Statistics: A Portrait of Aging Americans", reported 54.1 million adults or 16.3% of the US population are seniors including aged 65 or older. The senior population is expected to rise to 22% by 2040 and 25% by 2060. The growing demand for minimally invasive treatment surgeries has further created huge scope for the market growth.
The global thyroid ablation devices market is segmented by type, product, application and end-use. Based on the type, the market is sub-segmented into radiofrequency ablation, microwave ablation, and others. Where, others include image-guided ablation. Based on the product, the market is sub-segmented into thermal-based devices, and non-thermal-based devices. Based on the application, the market is sub-segmented into thyroid cancer, and thyroid nodules. Further, based on end-use, the market is sub-segmented into hospitals and clinics, ambulatory surgical centers, and others. Where, other include cancer specialty centers. Among the end-use, the hospitals and clinics sub-segment is anticipated to hold the largest market share during the forecast period. The large share of this segment is credited to the lower costs, higher efficiency, and availability.
Among the type, microwave ablation sub-segments expected to grow over the forecast period, owing to the owing to shorter treatment duration, a broader ablation zone, and less heat sink effect. A generator, a flexible cable, and an antenna make up the MWA system. An article published by Gland Surgery, namely "Microwave ablation for thyroid nodules: a new string to the bow for percutaneous treatments?" recorded experimental studies and studies on other organs, MWA could be a further step in percutaneous techniques for thyroid nodules, giving the advantage to reduce treatment time, reduce the heat sink effect, create an ellipsoidal ablated zone which best fits with the shaping of thyroid nodules.
The global thyroid ablation devices market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East &Africa, and Latin America. Among these, Asia-Pacific is anticipated to grow at a considerable CAGR over the forecast period. The growing demand for thyroid ablation devices, increasing geriatric population, the rising healthcare expenditure, and increasing incidences of thyroid cancer cases driving the thyroid ablation devices market in the Asia-Pacific.
North America is expected to hold a prominent share in the thyroid ablation devices market during the forecast period. The significant factors fueling the North America market include increasing prevalence of thyroid cancer, growing preference for minimally invasive surgeries and availability of technically sound ablation procedures. Further, the key players are expanding their presence into the region to cater to the demand for thyroid ablation devices in the market. In October 2023,STARmed Co., Ltd., a South Korean medical device company, launched its US subsidiary, STARmed America. This strategic move underscores STARmed's commitment to improving patient care in North America as part of its broader vision for global expansion. STARmed Co., Ltd. has been at the forefront of thermal ablation innovations, offering patient comfort through minimally invasive alternatives. The company focuses on Liver Radiofrequency Ablation (RFA), Radiofrequency Ablation (RFA), and engineered the first thyroid-specific RF electrodes in 2009.
The major companies serving the thyroid ablation devices market include Boston Scientific Corp., Integra LifeSciences Corp., Johnson & Johnson Services, Inc., Medtronic Plc, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2023, the US Food and Drug Administration (FDA) cleared Baird Medical's microwave ablation (MWA) system and disposable needles for use in the US. The clearance, which is through Baird Medical subsidiary Betters Medical, means doctors in the US can now use the technology to ablate thyroid nodules, breast tumors and other diseases where soft tissue needs to be removed. In July 2023, China's National Medical Products Administration (NMPA) approved the system to treat benign thyroid nodules.